ASCO 2024 Updates in the Treatment of Renal Cell Carcinoma and Evolving Data on Non-Clear Cell Renal Cell Carcinoma

home / between-the-lines / asco-2024-updates-in-the-treatment-of-renal-cell-carcinoma

Martin H. Voss, MD, and Moshe C. Ornstein, MD, review significant renal cell carcinoma research developments presented at ASCO 2024, highlighting data and insights poised to reshape the disease's treatment landscape.

2 KOLs are featured in this series

EP. 1: Overview of RCC Histology and Incidence Rates

Martin H. Voss, MD;Moshe Ornstein, MD, MA
June 26th 2024

Key opinion leaders explore renal cell carcinoma subtypes, their incidence rates, primary sites of origin, and frequently observed genetic mutations.

2 KOLs are featured in this series

EP. 2: CLEAR Trial Updates From ASCO 2024

Martin H. Voss, MD;Moshe Ornstein, MD, MA
June 26th 2024

Key opinion leaders analyze recent findings from the CLEAR trial presented at ASCO 2024, focusing on the four-year follow-up data for progression-free survival and overall survival outcomes.